Eniola's strongest angle is the 'talent that institutions missed' story, told in first person without false modesty: a PCN-licensed pharmacist from Lagos who, without a graduate degree or institutional lab, built a mathematically rigorous tripartite neuropharmacological framework from scratch, pre-registered five hypotheses, confirmed all five with ODE/RK45 and Bayesian MCMC, and attracted endorsements from faculty at Michigan, Harvard, Princeton, and NYU — then built three working software platforms on top of it. This is almost precisely Tyler Cowen's talent thesis made flesh. The project proposal should frame the CCT grant as funding the 'translation layer': complete IMPRINT and TOPOLOGIX as open-source clinical screening tools, advance the patent, and support the 12-month runway needed to push toward a phase-I trial architecture — with addiction framed not as a public-health cause but as a liberty-and-wellbeing problem (addiction destroys individual autonomy; a pharmacological prevention framework restores it). The collaborator endorsements from elite US institutions should appear organically, not as a credential parade.